Aurinia Pharmaceuticals Inc. (AUPH)

Trade AUPH now with
2/28/2023 6:16:51 AM Aurinia Pharmaceuticals Q4 Total Net Revenue $28.43 Mln Vs. $23.40 Mln Last Year
1/6/2023 6:04:41 AM Aurinia Pharmaceuticals Reports Q4 Net Revenue Of $28.40 Mln
11/3/2022 6:15:51 AM Aurinia Q3 Net Loss $9.0 Mln Or $0.06/Shr Vs Loss Of $50.3 Mln Or $0.39/Shr Last Year
8/4/2022 6:30:01 AM Aurinia Q2 Net Loss Of $35.5 Mln Or $0.25/shr Vs Net Loss Of $47.0 mln Or $0.37/shr Prior Year
7/22/2022 6:06:54 AM Aurinia Announces Positive CHMP Opinion For LUPKYNIS For Adults With Active Lupus Nephritis In Europe
6/3/2022 7:08:22 AM Aurinia : Data Shows LUPKYNIS Effective In Achieving Proteinuria Treatment Targets In Lupus Nephritis
5/10/2022 6:15:34 AM Aurinia Pharma Q1 Net Loss $37.6 Mln Or $0.27/shr Vs. Net Loss $50.4 Mln Or $0.40/shr Last Year
2/28/2022 6:06:41 AM Aurinia Q4 Net Loss $33.3 Mln Or $0.25/Shr Vs Loss Of $8.1 Mln Or $0.06/Shr Last Year
12/29/2021 10:48:49 AM Aurinia Pharmaceuticals Down 3%
12/9/2021 6:27:05 AM Aurinia Announces Positive Topline Results From AURORA 2 Continuation Study Of LUPKYNIS For Active Lupus Nephritis
11/1/2021 10:26:05 AM Aurinia:reductions In Proteinuria Sustained With No Impact On Renal Function At 30 Months Of Treatment With Voclosporin